Browsing by Author "Yesil H."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study
    (Studio K Krzysztof Molenda, 2015) Eskicioğlu F.; Turan G.A.; Sivrikoz O.N.; Cengiz H.; Akan Z.; Sahin N.; Yilmaz O.; Yesil H.; Vatansever S.
    Objectives: To determine the efficacy of montelukast in comparison with cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in rats. Material and methods: An experimental OHSS model was formed in 35 female Wistar rats. Rats (22 days old) were randomized into 5 groups, each containing 7 animals. The control group received no therapy; the mild OHSS group was administered pregnant mare serum gonadotropin (PMSG) 10 IU for 4 days, hCG 10 IU on the 5th day; the severe OHSS group received PMSG 10 IU for 4 days, hCG 30 IU on the 5th day. The montelukast group: received montelukast 10 mg/kg/day and the cabergoline group was administered cabergoline 100μg/kg/day via oral gavage for 6 days (days 22-27), in addition to those of severe OHSS. All groups were sacrificed on 28th day. Body weight, ovarian diameter and weight, vascular permeability, vascular endothelial growth factor (VEGF), semiquantitative VEGF receptor-1, and VEGF receptor-2 (VEGFR-2) immunohistochemistry were evaluated. Results: Ovarian diameter and VEGF expression were significantly lower in the montelukast and cabergoline groups than in the severe OHSS group. While montelukast was more effective in limiting vascular permeability in the severe OHSS, cabergoline was superior to montelukast with respect to the limiting effect on increased body weight and VEGFR-2 expression. Conclusions: The VEGF/VEGFR-2 interaction plays an important role in OHSS pathogenesis. Montelukast limits VEGF expression, and cabergoline reduces both VEGF and VEGFR-2 expressions; they are both effective therapies for the prevention of severe OHSS. © Polskie Towarzystwo Ginekologiczne.
  • No Thumbnail Available
    Item
    In vivo evaluation of cerium, gallium and vanadium-doped borate-based bioactive glass scaffolds using rat subcutaneous implantation model
    (Elsevier Ltd, 2016) Deliormanlı A.M.; Seda Vatansever H.; Yesil H.; Özdal-Kurt F.
    The main objective of this study was to evaluate the cerium, gallium and vanadium-containing bioactive borate glass scaffolds for soft tissue applications and determine the potential toxicity of these scaffolds on the adjacent tissues. The effects of the cerium, gallium and vanadium substitution on the soft tissue ingrowth and angiogenesis in porous borate based bioactive glass scaffolds were investigated using rat subcutaneous implantation model. For this purpose, bioactive borate glass powders containing therapeutic ions were prepared by melt-cast method and subsequently scaffolds were fabricated using polymer foam replication technique. The scaffolds were implanted subcutaneously for 4 weeks in Sprague Dawley rats. Bare borate glass scaffolds with the same microstructure were used as the control. Histology was used to evaluate tissue ingrowth and blood vessel formation in the implants. Additionally, the antibacterial activities of cerium, gallium and vanadium containing porous bioactive glass scaffolds were investigated in vitro by a zone inhibition method. Results revealed that addition of cerium ions to the borate glass network caused an increase in blood vessel formation. On the other hand, a decrease was obtained in angiogenesis in gallium and vanadium-containing glasses. All of the scaffolds prepared in the study did not show any antibacterial activity towards Escherichia coli and Staphylococcus aureus. © 2016 Elsevier Ltd and Techna Group S.r.l.